LEO Pharma (Rights of PDE4 Inhibitor Series) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

LEO Pharma (Rights of PDE4 Inhibitor Series) General Information

Description

The rights of phosphodiesterase type 4 inhibitor series based in Ballerup.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Industriparken 55
  • 2750 Ballerup
  • Denmark
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Pharmaceuticals
Corporate Office
  • Industriparken 55
  • 2750 Ballerup
  • Denmark

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LEO Pharma (Rights of PDE4 Inhibitor Series) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore LEO Pharma (Rights of PDE4 Inhibitor Series)‘s full profile, request access.

Request a free trial

LEO Pharma (Rights of PDE4 Inhibitor Series) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore LEO Pharma (Rights of PDE4 Inhibitor Series)‘s full profile, request access.

Request a free trial

LEO Pharma (Rights of PDE4 Inhibitor Series) FAQs

  • Where is LEO Pharma (Rights of PDE4 Inhibitor Series) headquartered?

    LEO Pharma (Rights of PDE4 Inhibitor Series) is headquartered in Ballerup, Denmark.

  • What industry is LEO Pharma (Rights of PDE4 Inhibitor Series) in?

    LEO Pharma (Rights of PDE4 Inhibitor Series)’s primary industry is Buildings and Property.

  • Is LEO Pharma (Rights of PDE4 Inhibitor Series) a private or public company?

    LEO Pharma (Rights of PDE4 Inhibitor Series) is a Private company.

  • What is LEO Pharma (Rights of PDE4 Inhibitor Series)’s current revenue?

    The current revenue for LEO Pharma (Rights of PDE4 Inhibitor Series) is .

  • Who are LEO Pharma (Rights of PDE4 Inhibitor Series)’s investors?

    LEO Pharma has invested in LEO Pharma (Rights of PDE4 Inhibitor Series).

  • When was LEO Pharma (Rights of PDE4 Inhibitor Series) acquired?

    LEO Pharma (Rights of PDE4 Inhibitor Series) was acquired on 23-Jul-2020.

  • Who acquired LEO Pharma (Rights of PDE4 Inhibitor Series)?

    LEO Pharma (Rights of PDE4 Inhibitor Series) was acquired by Union Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process